Featured Research

from universities, journals, and other organizations

Transplanted Human Stem Cells Prolong Survival In Mouse Model Of Rare Brain Disease

Date:
September 4, 2009
Source:
Cell Press
Summary:
A new study finds substantial improvement in a mouse model of a rare, hereditary neurodegenerative disease after transplantation of normal human neural stem cells. The research findings show that the transplanted cells provided a critical enzyme that was missing in the brains of the experimental mice and represent an important step toward what may be a successful therapeutic approach for a currently untreatable and devastating disease.

A new study finds substantial improvement in a mouse model of a rare, hereditary neurodegenerative disease after transplantation of normal human neural stem cells. The research findings, published by Cell Press in the September 4th issue of the journal Cell Stem Cell, show that the transplanted cells provided a critical enzyme that was missing in the brains of the experimental mice and represent an important step toward what may be a successful therapeutic approach for a currently untreatable and devastating disease.

Infantile neuronal ceroid lipofuscinosis (INCL), commonly known as Batten disease, is a fatal neurodegenerative disease in children. It is caused by a mutation in the gene that makes a crucial enzyme called palmitoyl protein thioesterase-1 (PPT1). A deficiency of PPT1 in the brain causes the abnormal accumulation of a cellular lipid storage material called lipofuscin, which leads to neuron death, a decline in cognitive and motor skills, visual impairment, seizures and premature death. Unfortunately, intravenous enzyme replacement therapy is not a viable treatment approach as it is nearly impossible to get the PPT1 enzyme into the brain.

Although there is currently no effective treatment for INCL, it has been hypothesized that transplanted donor cells might be able to secrete the needed enzyme directly into the host brain. A mouse model of INCL that mimics many aspects of the human disease has been developed and provides an excellent experimental model for testing whether a human neural stem cell transplant may be a beneficial disease treatment. Dr. Nobuko Uchida from StemCells, Inc., in Palo Alto, California led a study that tested this hypothesis with banked human neural stem cells that had been purified, expanded, and preserved.

"We took a novel approach and transplanted normal, nontumorigenic, and nongenetically modified human neural stem cells to deliver the deficient enzyme in the mouse model of INCL," explains Dr. Uchida. "We transplanted self-renewing human neural stem cells because, theoretically, these transplants can provide life-long production of the missing enzyme." Dr. Uchida and colleagues found that the purified human neural stem cells engrafted to the brain of INCL mice, migrated extensively, and produced enough PPT1 in the host mice to elicit significant improvement. Specifically, the INCL mice exhibited reduced lipofuscin, widespread neuroprotection, and a delayed loss of motor coordination.

"Early intervention with neural stem cell transplants into the brains of INCL patients may supply a continuous and long-lasting source of the missing PPT1 and provide some therapeutic benefit through protection of endogenous neurons," concludes Dr. Uchida. "These data support our rationale for continued development in humans and the potential for a medical breakthrough in this deadly disease." Notably, StemCells, Inc., recently reported positive results from the first Phase 1 clinical trials assessing the safety of these human neural stem cells as a potential treatment for Batten disease.

The researchers include Stanley J. Tamaki, StemCells, Inc., Palo Alto, CA; Yakop Jacobs, StemCells, Inc., Palo Alto, CA; Monika Dohse, StemCells, Inc., Palo Alto, CA; Alexandra Capela, StemCells, Inc., Palo Alto, CA; Jonathan D. Cooper, King's College London, London, UK; Michael Reitsma, StemCells, Inc., Palo Alto, CA; Dongping He, StemCells, Inc., Palo Alto, CA; Robert Tushinski, StemCells, Inc., Palo Alto, CA; Pavel V. Belichenko, Stanford University School of Medicine, Stanford, CA; Ahmad Salehi, Stanford University School of Medicine, Stanford, CA; William Mobley, Stanford University School of Medicine, Stanford, CA ; Fred H. Gage, The Salk Institute for Biological Studies, La Jolla, CA; Stephen Huhn, StemCells, Inc., Palo Alto, CA; Ann S. Tsukamoto, StemCells, Inc., Palo Alto, CA; Irving L. Weissman, Stanford University School of Medicine, Stanford, CA; and Nobuko Uchida, StemCells, Inc., Palo Alto, CA.


Story Source:

The above story is based on materials provided by Cell Press. Note: Materials may be edited for content and length.


Cite This Page:

Cell Press. "Transplanted Human Stem Cells Prolong Survival In Mouse Model Of Rare Brain Disease." ScienceDaily. ScienceDaily, 4 September 2009. <www.sciencedaily.com/releases/2009/09/090903163556.htm>.
Cell Press. (2009, September 4). Transplanted Human Stem Cells Prolong Survival In Mouse Model Of Rare Brain Disease. ScienceDaily. Retrieved April 23, 2014 from www.sciencedaily.com/releases/2009/09/090903163556.htm
Cell Press. "Transplanted Human Stem Cells Prolong Survival In Mouse Model Of Rare Brain Disease." ScienceDaily. www.sciencedaily.com/releases/2009/09/090903163556.htm (accessed April 23, 2014).

Share This



More Health & Medicine News

Wednesday, April 23, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Big Pharma Braces for M&A Wave

Big Pharma Braces for M&A Wave

Reuters - Business Video Online (Apr. 22, 2014) Big pharma on the move as Novartis boss, Joe Jimenez, tells Reuters about plans to transform his company via an asset exchange with GSK, and Astra Zeneca shares surge on speculation that Pfizer is looking for a takeover. Joanna Partridge reports. Video provided by Reuters
Powered by NewsLook.com
Study Says Most Crime Not Linked To Mental Illness

Study Says Most Crime Not Linked To Mental Illness

Newsy (Apr. 22, 2014) A new study finds most crimes committed by people with mental illness are not caused by symptoms of their illness or disorder. Video provided by Newsy
Powered by NewsLook.com
Hagel Gets Preview of New High-Tech Projects

Hagel Gets Preview of New High-Tech Projects

AP (Apr. 22, 2014) Defense Secretary Chuck Hagel is given hands-on demonstrations Tuesday of some of the newest research from DARPA _ the military's Defense Advanced Research Projects Agency program. (April 22) Video provided by AP
Powered by NewsLook.com
How Smaller Plates And Cutlery Could Make You Feel Fuller

How Smaller Plates And Cutlery Could Make You Feel Fuller

Newsy (Apr. 22, 2014) NBC's "Today" conducted an experiment to see if changing the size of plates and utensils affects the amount individuals eat. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

    Health News

    Environment News

    Technology News



    Save/Print:
    Share:

    Free Subscriptions


    Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

    Get Social & Mobile


    Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

    Have Feedback?


    Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
    Mobile: iPhone Android Web
    Follow: Facebook Twitter Google+
    Subscribe: RSS Feeds Email Newsletters
    Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins